MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
ProPhase Labs DPO Ratio 2011-2025 | PRPH
Annual DPO Ratio ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.4 | 53.2 | 0.139 | 21.7 | 19.1 | 25.9 | 71.9 | 42.9 | 30.9 | 44.1 | 58 | 52.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.9 | 0.139 | 38.8 |
Quarterly DPO Ratio ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.52 K | 1.36 K | - | 1.1 K | - | - | - | 77.5 | 65.1 | 56 | - | 22.4 | 55.6 | 36.9 | - | 78.9 | 145 | 83.1 | - | 123 | 147 | 130 | - | 20.4 | 28.4 | 22.1 | - | 23.7 | 20.7 | 23 | - | 19.7 | 29.1 | 181 | - | 163 | 198 | 196 | - | 54.1 | 76.3 | 34.4 | - | 37.6 | 60.6 | 34.9 | - | 43.3 | 91.2 | 47.8 | - | 58.7 | 111 | 59.3 | - | 54.3 | 95.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.52 K | 19.7 | 190 |
DPO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
309 | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
131 | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
116 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
52.8 | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
58.9 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
345 | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
212 | $ 3.07 | -6.25 % | $ 1.6 B | Canada |
 |
Agile Therapeutics
AGRX
|
352 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-807 | $ 5.11 | -5.46 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
41.8 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
519 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
75.6 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
39.3 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
55.8 | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
5.36 K | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
111 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
224 | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
29.4 | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
189 | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
33.4 | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
78.1 | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
94 | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
36.8 | - | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
37.3 | $ 26.61 | 1.22 % | $ 1.23 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
775 | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Rockwell Medical
RMTI
|
20.9 | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
32.3 | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
PetIQ
PETQ
|
54.2 | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
215 | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
62.7 | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
Radius Health
RDUS
|
274 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
6.63 | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
264 | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
194 | - | - | $ 1.08 B | USA |
 |
cbdMD
YCBD
|
84 | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
20.2 | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
53 | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
723 | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
211 | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
64 | $ 11.68 | 0.29 % | $ 14.2 B | USA |